Syncona launches ophthalmic gene therapy venture Beacon Therapeutics

Article

The new company debuted with £96 million in funding to target retinal diseases.

A scientist working at a computer station in a lab, where a gene is mapped on the screen behind her. Image credit: ©RFBSIP – stock.adobe.com

The new company, Beacon Therapeutics, will focus on "rare and prevalent retinal diseases." Image credit: ©RFBSIP – stock.adobe.com

Life sciences investment trust Syncona launched its newest venture, Beacon Therapeutics, on Monday. In a news release, representatives from Beacon Therapeutics spoke to the company’s development pipeline and gene therapies already underway. Beacon Therapeutics aims to be a leader in the ophthalmic gene therapy space, with a focus on "rare and prevalent retinal diseases that result in blindness."1

According to the release, Syncona Limited partnered with additional investors including OSE to provide the new therapeutic venture with £96 million ($120 million) in funding. In November 2022, Syncona acquired Applied Genetic Technologies Corporation (AGTC). Beacon Therapeutics called AGTC-501, a gene therapy program currently in Phase II clinical trials, its “lead clinical asset.” In a press release, the company said AGTC-501 will be used for treatment of X-linked retinitis pigmentosa (XLRP).2

The new company also announced two preclinical assets.1 First, an intravitreally (IVT) delivered novel AAV based program for dry age-related macular degeneration (dry AMD). The second is an asset targeting cone-rod dystrophy (CRD) caused by a null mutation in the CDHR1 gene.

Beacon Therapeutics launched a new location in London, UK. This is the company’s first facility in Europe; it has two US-based locations in Boston, Massachusetts and Alachua, Florida.

Professor Robert MacLaren, Professor of Ophthalmology, University of Oxford, a co-founder of Beacon Therapeutics, provided a statement for the news release. “Beacon Therapeutics is quite unique in being a company that at launch is already underpinned by excellent clinical trial data,” MacLaren said.1 “The company has both highly innovative retinal gene therapy programmes and the means to target them to the main causes of blindness in both the young and old.”

David Fellows will serve as the Chief Executive Officer of Beacon Therapeutics. Retinal expert Dr Nadia Waheed will serve as Chief Medical Officer. Dr Abraham Scaria was announced as Chief Scientific Officer, coming aboard from AGTC.

References

1. Beacon Therapeutics launches with £96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness. News release. Syncona Ltd; June 12, 2023. Accessed June 12, 2023. https://www.synconaltd.com/news-and-insights/news/beacon-therapeutics-launches-with-96-million-120-million-to-develop-a-new-generation-of-gene-therapies-for-retinal-diseases-resulting-in-blindness/
2. Launch of Beacon Therapeutics and New Scenic Clinical Trial Sponsorship. News release. Beacon Therapeutics; June 12, 2023. Accessed June 12, 2023.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.